Moderna
Manufacturing · Massachusetts, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
325 Binney St, Cambridge, Massachusetts,...Phone Number
(617) 714-6500Website
www.modernatx.comRevenue
$2.2 BillionStock Symbol
MRNAIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
15
1
3
2
2
2
About Moderna
Moderna is recognized as a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered. By blending scientific innovation with advanced technology, the company continues to transform how society prevents and addresses disease across infectious conditions, cancer, rare disorders and autoimmune challenges. Guided by a distinctive culture and a global team committed to improving human health, Moderna focuses on developing mRNA-based medicines that can make a meaningful and lasting impact.Explore more
Moderna Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moderna your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Moderna has recently received funding, and reach out quickly before it becomes old news!
Click to see if Moderna had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Moderna has new funding data
Moderna, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Moderna launches new products
Earning: See what the market has to say on Moderna recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Moderna is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Moderna
Recommended Actions
Find VP level buyers at Moderna
Find 2 more new buyers
Compare Similar Companies to Moderna
Compare insights from companies similar to Moderna, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Moderna is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Moderna is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Moderna.
Moderna financials insights
Gather financial insights about Moderna, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Other Financing Round
$25M
2015
Other Financing Round
$450M
2016
Multiple Rounds
$502M
2018
Multiple Rounds
$1.2B
2020
Multiple Rounds
$2.8B
2024
Other Financing Round
$750M
2025
Multiple Rounds
$2.1B
Moderna Tech Stack
Most Recent Scoops
Project
Moderna has advanced mRNA-4106, its cancer antigen therapy candidate for solid tumors, into a Phase I single monotherapy dose escalation study, reporting no safety findings to date, with Phase I data expected in the near term and proof-of-concept study data anticipated thereafter.
Proof of Concept (POC), Medical Research, Pharmaceuticals, Clinical Operations
Project
Moderna is entering mRNA-4200, its cancer antigen therapy candidate for solid tumors, into the clinic, leveraging safety and dosing data from the mRNA-4106 program to initiate monotherapy at a pre-identified safe and efficacious dose before combining with pembrolizumab in cycle 2, with Phase I endpoints of safety, tolerability, efficacy, and immunogenicity.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Moderna has reported Phase I/II clinical data for mRNA-4359 in combination with pembrolizumab in the first-line advanced melanoma setting, demonstrating an objective response rate of 10 out of 12 patients including 2 complete responses, with responses observed regardless of PD-L1 expression status and median progression-free survival not yet reached, alongside a manageable safety profile with no unexpected safety signals.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Moderna has reported Phase I/II clinical data for mRNA-4359 in combination with pembrolizumab in checkpoint-refractory advanced melanoma, demonstrating an objective response rate of 24% and a disease control rate of 60% across 25 evaluable patients, with an objective response rate of 67% observed in the PD-L1-positive subgroup and no dose-limiting toxicities or Grade 4/5 adverse events related to mRNA-4359 reported.
Medical Research, Pharmaceuticals, Clinical Operations
Partnership
Partnership, Clinical Operations
Moderna News & Media
Moderna secures up to 24 million RSV vaccine dose contract with Europe
Over 156,000 adults in Europe are hospitalised each year due to RSV, a virus that can cause severe lung issues.Moderna Appoints Michael McDonnell to Board of Directors - Newswire.com
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experienceModerna Stock Is Soaring. Is It Too Late to Buy?
Moderna's growth story is just beginning.Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives?
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Moderna
Sign Up For FreeTo access detailed company insights
Moderna is recognized as a pioneer in mRNA medicine, reshaping the way treatments and vaccines are created and delivered. By blending scientific innovation with advanced technology, the company continues to transform how society prevents and addresses disease across infectious conditions, cancer, rare disorders and autoimmune challenges. Guided by... Read More
